| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| King Pharmaceuticals has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Medical & Dental Adhesives & Sealants | 22 |
$500 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| KG: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | KING PHARMACEUTICALS INC (KG=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 24-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (KG). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (KG). | 5 |
$18 |
| 24-Nov-2009 | RiskMetrics Group |
N/A
| ISS Report on Klondike Gold Corp. | 8 |
$100 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| King Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
0.36% Nasdaq 
0.03 (0.25%) 
Research Reports
